|
US1548716A
(en)
|
1924-10-02 |
1925-08-04 |
Fournier Santiago Emilien |
Process for the manufacture of artificial freestone
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
ATE237694T1
(de)
|
1991-08-20 |
2003-05-15 |
Us Gov Health & Human Serv |
Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
|
|
US5252479A
(en)
|
1991-11-08 |
1993-10-12 |
Research Corporation Technologies, Inc. |
Safe vector for gene therapy
|
|
FR2688514A1
(fr)
|
1992-03-16 |
1993-09-17 |
Centre Nat Rech Scient |
Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
|
|
EP0673431A1
(en)
|
1992-12-03 |
1995-09-27 |
Genzyme Corporation |
Gene therapy for cystic fibrosis
|
|
EP0705344B8
(en)
|
1993-06-24 |
2006-05-10 |
Advec Inc. |
Adenovirus vectors for gene therapy
|
|
DE69435223D1
(de)
|
1993-10-25 |
2009-09-03 |
Canji Inc |
Rekombinanter Adenoviren-Vektor und Verfahren zur Verwendung
|
|
US5696234A
(en)
*
|
1994-08-01 |
1997-12-09 |
Schering Corporation |
Muteins of mammalian cytokine interleukin-13
|
|
US6682741B1
(en)
|
1998-06-10 |
2004-01-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
β2 microglobulin fusion proteins and high affinity variants
|
|
US7078387B1
(en)
|
1998-12-28 |
2006-07-18 |
Arch Development Corp. |
Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
|
|
US6287860B1
(en)
|
2000-01-20 |
2001-09-11 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of MEKK2 expression
|
|
CA2424158A1
(en)
|
2000-09-29 |
2002-04-11 |
The Scripps Research Institute |
Labeled peptides, and processes and intermediates useful for their preparation
|
|
WO2002074331A2
(en)
*
|
2001-03-19 |
2002-09-26 |
Isis Innovation Limited |
Mutated mhc molecules for use in immune suppression
|
|
ES2464532T3
(es)
|
2001-04-19 |
2014-06-03 |
The Scripps Research Institute |
Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
|
|
US8895020B2
(en)
|
2002-04-19 |
2014-11-25 |
Washington University |
Single chain trimers and uses therefor
|
|
WO2005081716A2
(en)
|
2003-11-24 |
2005-09-09 |
The Johns Hopkins University |
DNA VACCINES TARGETING ANTIGENS OF THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-CoV)
|
|
GB0329146D0
(en)
|
2003-12-16 |
2004-01-21 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
EA011619B1
(ru)
|
2005-06-20 |
2009-04-28 |
Кадила Хелзкэр Лимитед |
Экспрессионный вектор и способ продуцирования высоких уровней белков
|
|
US7521195B1
(en)
|
2005-07-21 |
2009-04-21 |
Celera Corporation |
Lung disease targets and uses thereof
|
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
CA2644712C
(en)
|
2006-03-06 |
2016-09-13 |
Amunix, Inc. |
Unstructured recombinant polymers and uses thereof
|
|
US8992937B2
(en)
|
2006-08-28 |
2015-03-31 |
Washington University |
Disulfide trap MHC class I molecules and uses therefor
|
|
CA2695374A1
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
|
WO2010098788A2
(en)
*
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
WO2010037395A2
(en)
|
2008-10-01 |
2010-04-08 |
Dako Denmark A/S |
Mhc multimers in cancer vaccines and immune monitoring
|
|
WO2010048313A2
(en)
*
|
2008-10-22 |
2010-04-29 |
Biogen Idec Ma Inc. |
Recombinant fcrn and variants thereof for purification of fc-containing fusion proteins
|
|
EP3269379A1
(en)
|
2008-11-30 |
2018-01-17 |
Immusant, Inc. |
Compositions and methods for treatment of celiac disease
|
|
DK3178835T3
(da)
|
2009-02-03 |
2019-06-24 |
Amunix Pharmaceuticals Inc |
Forlængede rekombinante polypeptider og sammensætninger omfattende samme
|
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
|
WO2012037551A2
(en)
|
2010-09-17 |
2012-03-22 |
Irx Therapeutics, Inc. |
Primary cell-derived biologic and wt1 synthetic long peptide vaccine
|
|
US20120141537A1
(en)
|
2010-11-18 |
2012-06-07 |
Pease Larry R |
Enhancing t cell activation using altered mhc-peptide ligands
|
|
WO2012088446A1
(en)
*
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
EP2663647A4
(en)
|
2011-01-14 |
2015-08-19 |
Redwood Bioscience Inc |
POLYPEPTIDE IMMUNOGLOBULINS WITH ALDEHYDIC MARKING AND THEIR USE METHOD
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
DK2699593T4
(da)
|
2011-04-20 |
2021-02-08 |
Univ Washington Through Its Center For Commercialization |
Beta-2 mikroglobulin-deficiente celler
|
|
WO2013022091A1
(ja)
|
2011-08-11 |
2013-02-14 |
小野薬品工業株式会社 |
Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
|
|
US9494588B2
(en)
|
2011-08-30 |
2016-11-15 |
Jacobs University Bremen Ggmbh |
Gene coded for a MHC class I molecule, plasmid, expression system protein, multimer, reagent and kit to analyze a T cell frequency
|
|
EP3520810A3
(en)
|
2012-01-13 |
2019-11-06 |
Memorial Sloan-Kettering Cancer Center |
Immunogenic wt1 peptides and use thereof
|
|
WO2013151664A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins
|
|
US9738724B2
(en)
|
2012-06-08 |
2017-08-22 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
|
EP3135690A1
(en)
|
2012-06-26 |
2017-03-01 |
Sutro Biopharma, Inc. |
Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
|
|
CN104582717B
(zh)
|
2012-07-19 |
2018-03-13 |
雷德伍德生物科技股份有限公司 |
对cd22有特异性的抗体及其使用方法
|
|
US9310374B2
(en)
|
2012-11-16 |
2016-04-12 |
Redwood Bioscience, Inc. |
Hydrazinyl-indole compounds and methods for producing a conjugate
|
|
SG11201504558TA
(en)
|
2012-12-11 |
2015-07-30 |
Einstein Coll Med |
Methods for high throughput receptor:ligand identification
|
|
AU2015209540B2
(en)
|
2014-01-21 |
2021-05-13 |
Albert Einstein College Of Medicine, Inc. |
Cellular platform for rapid and comprehensive T-cell immunomonitoring
|
|
KR20190072663A
(ko)
|
2014-04-25 |
2019-06-25 |
리나트 뉴로사이언스 코프. |
약물이 고도로 로딩된 항체-약물 접합체
|
|
AU2015271100B2
(en)
|
2014-06-06 |
2020-07-30 |
Redwood Bioscience, Inc. |
Anti-HER2 antibody-maytansine conjugates and methods of use thereof
|
|
JP6652932B2
(ja)
|
2014-06-18 |
2020-02-26 |
アルバート アインシュタイン カレッジ オブ メディシン |
ｓｙｎＴａｃポリペプチド及びその使用
|
|
EP3286222A4
(en)
|
2015-03-23 |
2018-08-08 |
The Johns Hopkins University |
Hla-restricted epitopes encoded by somatically mutated genes
|
|
US10472412B2
(en)
|
2015-03-25 |
2019-11-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific multivalent fusion proteins
|
|
IL304950A
(en)
*
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
EP3292152A1
(en)
*
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
|
CA3014458A1
(en)
*
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
WO2017151940A2
(en)
*
|
2016-03-03 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
SG11201808196UA
(en)
|
2016-03-31 |
2018-10-30 |
Neon Therapeutics Inc |
Neoantigens and methods of their use
|
|
IL262606B2
(en)
|
2016-05-18 |
2023-04-01 |
Albert Einstein College Medicine Inc |
pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
|
|
SG11201808552XA
(en)
|
2016-05-18 |
2018-10-30 |
Cue Biopharma Inc |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
DE102016222109A1
(de)
|
2016-11-10 |
2018-05-17 |
Robert Bosch Gmbh |
Brennstoffzellensystem
|
|
CN110325205B
(zh)
*
|
2016-12-22 |
2023-08-15 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US11851471B2
(en)
|
2017-01-09 |
2023-12-26 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
US11725210B2
(en)
|
2017-03-17 |
2023-08-15 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
WO2019051127A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
WO2019051126A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
ANTIGEN PRESENTING POLYPEPTIDES COMPRISING CHEMICAL CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
MX2020002596A
(es)
|
2017-09-07 |
2020-07-20 |
Cue Biopharma Inc |
Polipeptidos moduladores de linfocitos t multimericos y metodos de uso de estos.
|
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
ANTIGEN-PRESENTING POLYPEPTIDES AND METHOD FOR THEIR USE
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
KR20200138334A
(ko)
|
2018-04-02 |
2020-12-09 |
팩트 파마, 인크. |
펩티드-MHC comPACT
|
|
WO2020132365A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
WO2020132135A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3897690A4
(en)
|
2018-12-19 |
2022-09-28 |
Cue Biopharma, Inc. |
T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
EP3897746A4
(en)
|
2018-12-19 |
2022-10-26 |
Cue Biopharma, Inc. |
MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
TWI856047B
(zh)
|
2018-12-19 |
2024-09-21 |
美商信號生物製藥公司 |
多聚體ｔ細胞調節多肽及其使用方法
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2020132366A2
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
JP2022521738A
(ja)
|
2019-02-20 |
2022-04-12 |
ルビウス セラピューティクス， インコーポレイテッド |
負荷可能な抗原提示ポリペプチドを含む操作された赤血球系細胞および使用方法
|
|
JP7691927B2
(ja)
|
2019-03-06 |
2025-06-12 |
キュー バイオファーマ， インコーポレイテッド |
Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
|
|
WO2020181062A1
(en)
|
2019-03-06 |
2020-09-10 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
KR20220015382A
(ko)
|
2019-05-29 |
2022-02-08 |
큐 바이오파마, 인크. |
다량체 t-세포 조절 폴리펩타이드 및 이의 사용 방법
|
|
JP2022536581A
(ja)
|
2019-06-19 |
2022-08-18 |
キュー バイオファーマ， インコーポレイテッド |
多量体ｔ細胞調節性ポリペプチド及びその使用方法
|
|
EP4030897A4
(en)
|
2019-09-20 |
2023-10-18 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
AU2020357944A1
(en)
|
2019-09-30 |
2022-03-31 |
Adimab, Llc |
CH1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
|
|
CN114599674A
(zh)
|
2019-10-23 |
2022-06-07 |
库尔生物制药有限公司 |
T细胞调节嵌合分子及其使用方法
|
|
WO2021081232A1
(en)
|
2019-10-23 |
2021-04-29 |
Cue Biopharma, Inc. |
Modified cytotoxic t cells and methods of use thereof
|
|
WO2021195108A1
(en)
|
2020-03-24 |
2021-09-30 |
Cue Biopharma, Inc. |
T cell modulatory polypeptides and methods of use thereof
|
|
US20230117521A1
(en)
|
2020-03-25 |
2023-04-20 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
|
|
IL296209A
(en)
|
2020-05-12 |
2022-11-01 |
Cue Biopharma Inc |
Multimeric t-cell modulatory polypeptides and methods of using them
|
|
WO2021242935A1
(en)
|
2020-05-26 |
2021-12-02 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
WO2022015880A2
(en)
|
2020-07-14 |
2022-01-20 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides with conjugation sites and methods of use thereof
|
|
JP2023541366A
(ja)
|
2020-09-09 |
2023-10-02 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
|
|
WO2022056015A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof
|
|
US20240082411A1
(en)
|
2020-11-06 |
2024-03-14 |
Cue Biopharma, Inc. |
T-Cell Modulatory Polypeptides with Conjugation Sites and Methods of Use Thereof
|
|
WO2022099157A1
(en)
|
2020-11-06 |
2022-05-12 |
Cue Biopharma, Inc. |
Antigen presenting polypeptide complexes and methods of use thereof
|
|
WO2022119958A1
(en)
|
2020-12-02 |
2022-06-09 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
EP4308143A4
(en)
|
2021-03-19 |
2025-06-04 |
Cue Biopharma, Inc. |
T-cell modulatory polypeptides and methods of use thereof
|
|
CN117222421A
(zh)
|
2021-03-19 |
2023-12-12 |
Cue生物制药股份有限公司 |
T细胞调节多肽和其使用方法
|
|
WO2022226073A1
(en)
|
2021-04-21 |
2022-10-27 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory polypeptides and methods of use thereof
|
|
JP2024515205A
(ja)
|
2021-04-21 |
2024-04-05 |
キュー バイオファーマ，インコーポレーテッド |
ＴＧＦ－βを持つ抗原提示ポリペプチド複合体及びその使用方法
|
|
JP2024517658A
(ja)
|
2021-04-21 |
2024-04-23 |
キュー バイオファーマ， インコーポレイテッド |
１型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節ポリペプチド及びその使用方法
|
|
WO2023081718A1
(en)
|
2021-11-04 |
2023-05-11 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|